Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Dermatology Reports
Erschienen in: Current Dermatology Reports 4/2022

06.10.2022 | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Off-Label Uses of Rituximab in Dermatology

verfasst von: Connor Cole, Kyle T. Amber

Erschienen in: Current Dermatology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Rituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions.

Recent Findings

Key recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus.

Summary

Data from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculitis. More limited data suggests its use in recalcitrant cases of diseases such as pemphigoid, epidermolysis bullosa acquisita, and dermatomyositis. There is scarce evidence and mixed results for rituximab when studied in cutaneous polyarteritis nodosa and cutaneous lupus erythematosus.
Literatur
1.
Bhandari PR, Pai VV. Novel applications of rituximab in dermatological disorders. Indian Dermatol Online J. 2014;5(3):250–9.CrossRef
2.
Gleghorn K, Wilson J, Wilkerson M. Rituximab: uses in dermatology. Skin Therapy Lett. 2016;21(5):5–7.
3.
Espana A, Ornilla E, Panizo C. Rituximab in dermatology. Actas Dermosifiliogr. 2013;104(5):380–92.CrossRef
4.
Hertl M, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6(5):366–73.CrossRef
5.
Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12(1):3.CrossRef
6.
Carr DR, Heffernan MP. Off-label uses of in dermatology. Dermatol Ther. 2007;20(4):277–87.CrossRef
7.
Arin MJ, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–5.CrossRef
8.
Esposito M, et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol. 2006;86(1):87–9.
9.
Schmidt E, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503–8.CrossRef
10.
Maloney DG, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–66.CrossRef
11.
Emer JJ, Claire W. Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2009;2(5):29–37.
12.
Ahmed AR, Shetty S. The emerging role of rituximab in autoimmune blistering diseases. Am J Clin Dermatol. 2015;16(3):167–77.CrossRef
13.
Pollmann R, et al. Identification of autoreactive B cell subpopulations in peripheral blood of autoimmune patients with pemphigus vulgaris. Front Immunol. 2019;10:1375.CrossRef
14.
Tokunaga M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology. 2005;44(2):176–82.CrossRef
15.
Tokunaga M, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5.CrossRef
16.
Sfikakis PP, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501–13.CrossRef
17.
Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005;17(5):550–7.CrossRef
18.
Desai-Mehta A, et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996;97(9):2063–73.CrossRef
19.
Toubi E, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(6):818–20.CrossRef
20.
Vigna-Perez M, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.CrossRef
21.
Sfikakis PP, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123(1):66–73.CrossRef
22.
Vallerskog T, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(1):62–74.CrossRef
23.
Nagel A, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129(9):2202–10.CrossRef
24.
Maloney DG, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgki’s lymphoma. Blood. 1997;90(6):2188–95.CrossRef
25.
Davies A, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014;15(3):343–52.CrossRef
26.
Roll P, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377–86.CrossRef
27.
Ng KP, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66(9):1259–62.CrossRef
28.
Rider LG, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32(5):689–96.
29.
• Joly P, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40. This important study from Joly et al demonstrated the superiority of rituximab plus steroids compared to steroid monotherapy in the treatment of pemphigus. This work was fundamental in rituximab being approved by the FDA in 2018 for the treatment of moderate-to-severe pemphigus.
30.
Fink-Puches R, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847–53.CrossRef
31.
Kerl K, et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155(6):1197–200.CrossRef
32.
Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk. 2011;11(3):286–8.CrossRef
33.
Ahmed AR, Kaveri S. Reversing autoimmunity combination of rituximab and intravenous immunoglobulin. Front Immunol. 2018;9:1189.CrossRef
34.
Kushner CJ, et al. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404–9.CrossRef
35.
Rashid H, et al. The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: daily practice data from a retrospective study. J Am Acad Dermatol. 2020;83(5):1503–5.CrossRef
36.
Tovanabutra N, et al. Temporal outcomes after rituximab therapy for pemphigus vulgaris. J Invest Dermatol. 2022;142(4):1058–64.CrossRef
37.
You C, et al. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1221–8.CrossRef
38.
Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther. 2003;5(Suppl 4):S12–6.CrossRef
39.
Cheungpasitporn W, et al. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2017;6(1):18–25.CrossRef
40.
Linschoten M, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–308.CrossRef
41.
Lazzerini PE, et al. Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad. Immunol Res. 2017;65(1):262–75.CrossRef
42.
Kilickap S, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma. Med Oncol. 2008;25(4):437–42.CrossRef
43.
Chen DM, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111–9.CrossRef
44.
Werth VP, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384(24):2295–305.CrossRef
45.
Agarwal A, et al. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis. PLoS ONE. 2018;13(9):e0198074.CrossRef
46.
MacIsaac J, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion. 2018;58(11):2729–35.CrossRef
47.
Emery P, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–400.CrossRef
48.
McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33.CrossRef
49.
Looney RJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9.CrossRef
50.
Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834–40.CrossRef
51.
Amber KT, et al. The controversy of hepatitis C and rituximab: a multidisciplinary dilemma with implications for patients with pemphigus. Indian J Dermatol Venereol Leprol. 2016;82(2):182–3.CrossRef
52.
Quartuccio L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88–93.CrossRef
53.
Buch MH, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–20.CrossRef
54.
Colquhoun M, et al. Rituximab administration during the 2nd trimester of pregnancy for systemic lupus erythematosus: case report and review of the literature in rheumatic disease. Mod Rheumatol Case Rep. 2021;6(2):173–7.CrossRef
55.
Seyed Ahadi M, et al. Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study. Caspian J Intern Med. 2021;12(Suppl 2):S491–4.
56.
Evens AM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170–80.CrossRef
57.
Mozessohn L, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22(10):842–9.CrossRef
58.
Pei SN, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91(7):1007–12.CrossRef
59.
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–309.CrossRef
60.
Ceccarelli L, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65(2):180–3.CrossRef
61.
Myers RP, et al. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15(9):599–603.CrossRef
62.
Sagnelli E, et al. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol. 2012;2012:945950.CrossRef
63.
Ennishi D, et al. Does rituximab really induce hepatitis C virus reactivation? J Clin Oncol. 2008;26(28):4695–6 author reply 4696.CrossRef
64.
Saag KG, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.CrossRef
65.
Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci. 2017;11(2):41–4.
66.
Ottaviani S, et al. Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80(4):435–6.CrossRef
67.
Amber KT, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78(15):1527–48.CrossRef
68.
Gottenberg JE, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32.CrossRef
69.
Strangfeld A, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–42.CrossRef
70.
Mahmoudi H, et al. Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study. J Am Acad Dermatol. 2021;84(4):1098–100.CrossRef
71.
Joly P, French study Group on auto immune bullous skin diseases, and the French network of rare diseases in Dermatology (FIMARAD). Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. J Am Acad Dermatol. 2022;86(2):494–7.CrossRef
72.
Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100(11):2805–12.CrossRef
73.
Eming R, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.CrossRef
74.
Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148(3):602–3.CrossRef
75.
Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.CrossRef
76.
Murrell DF, Sprecher E. Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2017;177(5):1143–4.CrossRef
77.
Vinay K, et al. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–8.CrossRef
78.
Fuertes I, et al. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology. 2010;221(1):13–6.CrossRef
79.
Borradori L, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137(3):269–72.
80.
Heizmann M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66(2):142–4.CrossRef
81.
Fatourechi MM, El-Azhary RA, Gibson LE. Rituximab: applications in dermatology. Int J Dermatol. 2006;45(10):1143–55.CrossRef
82.
Goebeler M, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149(4):899–901.CrossRef
83.
Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018;17(10):1002–10.CrossRef
84.
Feliciani C, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867–77.CrossRef
85.
Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol. 2020;82(5):1237–9.CrossRef
86.
Ahmed AR, et al. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74(4):700–8.CrossRef
87.
Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173(1):302–4.CrossRef
88.
Polansky M, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179–86.CrossRef
89.
Kolesnik M, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28(6):771–80.CrossRef
90.
Lourari S, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25(10):1238–40.CrossRef
91.
Kasperkiewicz M, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8.CrossRef
92.
Bilgic Temel A, et al. Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments. Case Rep Dermatol. 2017;9(1):38–44.CrossRef
93.
Tomsitz D, Stefaniak R, Worm M. Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients. Br J Dermatol. 2015;172(3):829–31.CrossRef
94.
Batts AF, et al. Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab. JAAD Case Rep. 2016;2(1):7–9.CrossRef
95.
Tourte M, et al. Pemphigoid gestationis: a successful preventive treatment by rituximab. J Eur Acad Dermatol Venereol. 2017;31(4):e206–7.CrossRef
96.
Cianchini G, et al. Severe persistent pemphigoid gestationis: long-term remission with rituximab. Br J Dermatol. 2007;157(2):388–9.CrossRef
97.
Ridpath AV, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018;57(11):1372–4.CrossRef
98.
Sowerby L, et al. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017;153(6):603–5.CrossRef
99.
Kremer N, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209–16.CrossRef
100.
Lamberts A, et al. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248.CrossRef
101.
Schmidt E, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.CrossRef
102.
Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol. 2020;38(3):384–96.CrossRef
103.
Murrell DF, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168–74.CrossRef
104.
Li Y, Foshee JB, Sontheimer RD. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. J Am Acad Dermatol. 2011;64(4):773–8.CrossRef
105.
Maley A, et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2016;74(5):835–40.CrossRef
106.
Nishimura R, et al. Refractory mucous membrane pemphigoid which developed after allogeneic stem cell transplantation and was successfully treated with rituximab. Eur J Dermatol. 2013;23(4):562–4.CrossRef
107.
Schumann T, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol. 2009;89(1):101–2.CrossRef
108.
Taverna JA, et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol. 2007;6(7):731–2.
109.
Amir Dastmalchi D, et al. The efficacy of rituximab in patients with mucous membrane pemphigoid. J Dermatolog Treat. 2022;33(2):1084–90.CrossRef
110.
Le Roux-Villet C, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843–9.CrossRef
111.
Lytvyn Y, et al. Biologic treatment outcomes in mucous membrane pemphigoid: a systematic review. J Am Acad Dermatol. 2021;87(1):110–20.CrossRef
112.
Haefliger S, et al. Rituximab for the treatment of isolated refractory desquamative gingivitis due to mucous membrane pemphigoid. JAMA Dermatol. 2016;152(12):1396–8.CrossRef
113.
Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861–9.CrossRef
114.
Rubsam A, et al. Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther. 2015;15(7):927–33.CrossRef
115.
Steger B, et al. Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis-an interventional case series. Cornea. 2016;35(12):1611–4.CrossRef
116.
Tazudeen N, et al. IgM ocular cicatricial pemphigoid: a unique insight into the immune system. Dermatol Online J. 2015;21(10).
117.
Wollina U, et al. Monoclonal anti-CD20 antibody therapy in cicatrical pemphigoid with oral and hypopharyngeal involvement and related conditions. J Clin Aesthet Dermatol. 2013;6(5):45–8.
118.
Lambiel S, et al. Paraneoplastic mucous membrane pemphigoid with ocular and laryngeal involvement. BMJ Case Rep. 2017.
119.
Wilder E, Fernandez MP, Krejci-Manwaring J. Mucous membrane pemphigoid involving the trachea and bronchi: an extremely rare and life-threatening presentation. Cutis. 2016;98(3):E24–7.
120.
Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012;39(5):477–9.CrossRef
121.
Oktem A, et al. Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. J Dermatolog Treat. 2017;28(1):50–4.CrossRef
122.
Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156(1):194–6.CrossRef
123.
McKinley SK, et al. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatr Dermatol. 2014;31(2):241–4.CrossRef
124.
Niedermeier A, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143(2):192–8.CrossRef
125.
Sadler E, et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007;157(2):417–9.CrossRef
126.
Saha M, et al. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34(8):e979–80.CrossRef
127.
Schmidt E, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142(2):147–50.CrossRef
128.
Bevans SL, Sami N. The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. Dermatol Ther. 2018;31(6):e12726.CrossRef
129.
Cavailhes A, et al. Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Ann Dermatol Venereol. 2009;136(11):795–9.CrossRef
130.
Mendes SR, Coutinho I, Cardoso JC. Epidermolysis bullosa acquisita treated with rituximab. BMJ Case Rep. 2021;14(7):e243432.CrossRef
131.
Iwata H, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018;13(1):153.CrossRef
132.
Kubisch I, et al. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol. 2010;11(4):289–93.
133.
Koga H, et al. Epidermolysis bullosa acquisita: the 2019 update. Front Med. 2018;5:362.CrossRef
134.
Allenbach Y, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial. PLoS ONE. 2015;10(11):e0133702.CrossRef
135.
Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763–7.CrossRef
136.
Bader-Meunier B, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.CrossRef
137.
Garcia Hernandez FJ, et al. Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy. Med Clin. 2010;135(6):256–9.
138.
Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34(9):1864–8.
139.
Bauhammer J, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016;43(8):1566–74.CrossRef
140.
Andersson H, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology. 2015;54(8):1420–8.CrossRef
141.
Sem M, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology. 2009;48(8):968–71.CrossRef
142.
Sharp C, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology. 2016;55(7):1318–24.CrossRef
143.
Basnayake C, et al. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol. 2015;34(2):371–7.CrossRef
144.
Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol. 2009;15(7):338–40.CrossRef
145.
Unger L, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53(9):1630–8.CrossRef
146.
Kuye IO, Smith GP. The Use of Rituximab in the Management of Refractory Dermatomyositis. J Drugs Dermatol. 2017;16(2):162–6.
147.
Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013;31(6):896–903.
148.
Valiyil R, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62(9):1328–34.CrossRef
149.
Egeli BH, et al. Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study. Clin Rheumatol. 2022;41(1):123–7.CrossRef
150.
Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest. 2017;152(6):1283–95.CrossRef
151.
Oddis CV, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.CrossRef
152.
Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56(11):1399–403.CrossRef
153.
Ogawa Y, et al. Effective administration of rituximab in anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review. Case Rep Rheumatol. 2017;2017:5386797.
154.
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601–7.CrossRef
155.
Aggarwal R, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology. 2017;56(2):247–54.CrossRef
156.
Dinh HV, et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56(1):148–53.CrossRef
157.
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–53.CrossRef
158.
Aggarwal R, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740–9.CrossRef
159.
Leclair V, et al. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology. 2019;58(7):1214–20.CrossRef
160.
Barsotti S, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018;70(2):78–84.CrossRef
161.
Mahler EA, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50(12):2206–13.CrossRef
162.
• Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. This study was one of the key randomized controlled trials showing the non-inferiority of rituximab as compared to cyclophosphamide for induction of remission of ANCA-associated vasculitis. This, along with several other studies, helped lead to the FDA approval of rituximab for the treatment of GPA and MPA in 2011.
163.
Jones RB, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.CrossRef
164.
Jones RB, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–82.CrossRef
165.
Smith RM, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243–9.CrossRef
166.
Menditto VG, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology. 2021;60(4):1640–50.CrossRef
167.
Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review. Autoimmun Rev. 2021;20(2):102737.CrossRef
168.
Guillevin L, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.CrossRef
169.
Terrier B, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150–6.CrossRef
170.
Charles P, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143–9.CrossRef
171.
Charles P, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173(3):179–87.CrossRef
172.
Gopaluni S, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017;18(1):112.CrossRef
173.
Sonomoto K, et al. A case of polyarteritis nodosa successfully treated by rituximab. Nihon Rinsho Meneki Gakkai Kaishi. 2008;31(2):119–23.CrossRef
174.
Eleftheriou D, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology. 2009;48(8):978–86.CrossRef
175.
Bansal NK, Houghton KM. Cutaneous polyarteritis nodosa in childhood: a case report and review of the literature. Arthritis. 2010;2010:687547.CrossRef
176.
Neel A, et al. Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol. 2011;17(8):439–41.CrossRef
177.
da Silva LS, et al. Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review. Rev Bras Reumatol. 2015;55(6):531–5.CrossRef
178.
Ribeiro E, et al. Rituximab efficacy during a refractory polyarteritis nodosa flare. Case Rep Med. 2009;2009:738293.CrossRef
179.
Krishnan S, Bhakuni DS, Kartik S. Rituximab in refractory cutaneous polyarteritis. Int J Rheum Dis. 2012;15(5):e127.CrossRef
180.
Rees F, Yazdani R, Lanyon P. Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol. 2011;30(9):1241–5.CrossRef
181.
Campanilho-Marques R, et al. Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab. Joint Bone Spine. 2014;81(3):277–8.CrossRef
182.
Matsuo S, et al. The successful treatment of refractory polyarteritis nodosa using infliximab. Intern Med. 2017;56(11):1435–8.CrossRef
183.
Rimar D, et al. Tofacitinib for polyarteritis nodosa: a tailored therapy. Ann Rheum Dis. 2016;75(12):2214–6.CrossRef
184.
Krusche M, et al. Tocilizumab treatment for polyarteritis nodosa. Rheumatology. 2020;59(10):e63–5.CrossRef
185.
Shirai T, et al. Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. Scand J Rheumatol. 2019;48(4):308–14.CrossRef
186.
Papachristodoulou E, et al. Therapeutic options for cutaneous polyarteritis nodosa: a systematic review. Rheumatology. 2021;60(9):4039–47.CrossRef
187.
Dammacco F, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343–53.CrossRef
188.
De Vita S, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–53.CrossRef
189.
Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835–42.CrossRef
190.
• Kaegi C, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990. This systematic review includes analysis of 118 patients with cryoglobulinemia treated with rituximab and comprises the key data showing the utility of the drug in this disease.
191.
Saadoun D, et al. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study. J Autoimmun. 2021;116:102577.CrossRef
192.
Wink F, Houtman PM, Jansen TL. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol. 2011;30(2):293–300.CrossRef
193.
Lesniak K, et al. Noninfectious, severe cryoglobulinemic vasculitis with renal involvement - safety and efficacy of long-term treatment with rituximab. Int J Nephrol Renovasc Dis. 2021;14:267–77.CrossRef
194.
Ferri C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48–55.CrossRef
195.
Saadoun D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326–34.CrossRef
196.
Sy-Go JPT, et al. Rituximab-associated flare of cryoglobulinemic vasculitis. Kidney Int Rep. 2021;6(11):2840–9.CrossRef
197.
Desbois AC, et al. Rituximab-associated vasculitis flare: incidence, predictors, and outcome. J Rheumatol. 2020;47(6):896–902.CrossRef
198.
Sene D, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848–55.CrossRef
199.
Fairley JL, et al. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2020;50(1):95–127.CrossRef
200.
da Costa RQ, et al. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432–40.CrossRef
201.
Vital EM, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(6):1586–91.CrossRef
202.
Hofmann SC, et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus–report of 17 cases and review of the literature. Lupus. 2013;22(9):932–9.CrossRef
203.
Moreno-Suarez F, Pulpillo-Ruiz A. Rituximab for the treatment of lupus erythematosus panniculitis. Dermatol Ther. 2013;26(5):415–8.
Metadaten
Titel
Off-Label Uses of Rituximab in Dermatology
verfasst von
Connor Cole
Kyle T. Amber
Publikationsdatum
06.10.2022
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 4/2022
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-022-00375-4

Weitere Artikel der Ausgabe 4/2022

Current Dermatology Reports 4/2022 Zur Ausgabe

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Pemphigus for the Inpatient Dermatologist

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review

Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient

Covid-19 in Dermatology (J. M. Gelfand, Section editor)

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Contact Dermatitis (B.Adler and V. Deleo, Section editors)

Tattoo-Related Allergic Contact Dermatitis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise